Christian M Capitini1, Terry J Fry, Crystal L Mackall. 1. Immunology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Abstract
PROBLEM STATEMENT: The development of a potent vaccine that can help treat tumors resistant to conventional cytotoxic therapies remains elusive. While part of the problem may be that trials have focused on patients with bulky residual disease, the desire to maximize responses to the vaccine remains. APPROACH: The gamma(c) family of cytokines offer a unique opportunity to support the expansion and effector potential of vaccine-responding T-cells, as well as stimulate other effectors, such as natural killer (NK) cells, to become activated. RESULTS: Combining vaccines with cytokines seems logical but can bring unwanted toxicity, as has been observed with interleukin (IL)-2. In addition, the nonspecific activation or expansion of unwanted cell subsets, such as regulatory T-cells, can contribute to global immunosuppression and limit vaccine responses. The development of IL-7 and IL-21 for the clinic offers the promise of enhancing anti-tumor responses but with far less systemic toxicity and no expansion of regulatory T cells. Preclinical studies demonstrate that IL-15 could also improve T-cell, and especially NK-cell, responses as well. CONCLUSIONS/RECOMMENDATIONS: Future work should expand the use of vaccines with IL-7, IL-21 and hopefully IL-15 in high-risk patients, and consider treatment while in a state of minimal residual disease to maximize benefit. Identifying tumors that can signal through gamma(c) cytokines will also be essential so that induction of relapse will be avoided.
PROBLEM STATEMENT: The development of a potent vaccine that can help treat tumors resistant to conventional cytotoxic therapies remains elusive. While part of the problem may be that trials have focused on patients with bulky residual disease, the desire to maximize responses to the vaccine remains. APPROACH: The gamma(c) family of cytokines offer a unique opportunity to support the expansion and effector potential of vaccine-responding T-cells, as well as stimulate other effectors, such as natural killer (NK) cells, to become activated. RESULTS: Combining vaccines with cytokines seems logical but can bring unwanted toxicity, as has been observed with interleukin (IL)-2. In addition, the nonspecific activation or expansion of unwanted cell subsets, such as regulatory T-cells, can contribute to global immunosuppression and limit vaccine responses. The development of IL-7 and IL-21 for the clinic offers the promise of enhancing anti-tumor responses but with far less systemic toxicity and no expansion of regulatory T cells. Preclinical studies demonstrate that IL-15 could also improve T-cell, and especially NK-cell, responses as well. CONCLUSIONS/RECOMMENDATIONS: Future work should expand the use of vaccines with IL-7, IL-21 and hopefully IL-15 in high-risk patients, and consider treatment while in a state of minimal residual disease to maximize benefit. Identifying tumors that can signal through gamma(c) cytokines will also be essential so that induction of relapse will be avoided.
Authors: S Horiuchi; Y Koyanagi; Y Tanaka; M Waki; A Matsumoto; Y W Zhou; M Yamamoto; N Yamamoto Journal: Immunology Date: 1997-05 Impact factor: 7.397
Authors: S A Rosenberg; Y Zhai; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; C A Seipp; J H Einhorn; B Roberts; D E White Journal: J Natl Cancer Inst Date: 1998-12-16 Impact factor: 13.506
Authors: Daniel J Powell; Mark E Dudley; Katherine A Hogan; John R Wunderlich; Steven A Rosenberg Journal: J Immunol Date: 2006-11-01 Impact factor: 5.422
Authors: M C Panelli; J Wunderlich; J Jeffries; E Wang; A Mixon; S A Rosenberg; F M Marincola Journal: J Immunother Date: 2000 Jul-Aug Impact factor: 4.456
Authors: Lara Cattaruzza; Annunziata Gloghini; Karin Olivo; Raffaele Di Francia; Debora Lorenzon; Rosaria De Filippi; Antonino Carbone; Alfonso Colombatti; Antonio Pinto; Donatella Aldinucci Journal: Int J Cancer Date: 2009-09-01 Impact factor: 7.396
Authors: Mehran Habibi; Maciej Kmieciak; Laura Graham; Johanna K Morales; Harry D Bear; Masoud H Manjili Journal: Breast Cancer Res Treat Date: 2008-04-20 Impact factor: 4.872
Authors: M Lotem; E Shiloni; I Pappo; O Drize; T Hamburger; R Weitzen; R Isacson; L Kaduri; S Merims; S Frankenburg; T Peretz Journal: Br J Cancer Date: 2004-02-23 Impact factor: 7.640
Authors: Yin Guo; Liming Luan; Whitney Rabacal; Julia K Bohannon; Benjamin A Fensterheim; Antonio Hernandez; Edward R Sherwood Journal: J Immunol Date: 2015-07-27 Impact factor: 5.422
Authors: D G Roy; K Geoffroy; M Marguerie; S T Khan; N T Martin; J Kmiecik; D Bobbala; A S Aitken; C T de Souza; K B Stephenson; B D Lichty; R C Auer; D F Stojdl; J C Bell; M-C Bourgeois-Daigneault Journal: Nat Commun Date: 2021-05-11 Impact factor: 14.919
Authors: Qi-ling Li; Shang-feng Gao; Yun-ping Wang; Jun Ma; Cai-xia Feng; Ying Wang; Yue-ling Wang Journal: Ann Saudi Med Date: 2012 Mar-Apr Impact factor: 1.526
Authors: Saskia J A M Santegoets; Annelies W Turksma; Megan M Suhoski; Anita G M Stam; Steve M Albelda; Erik Hooijberg; Rik J Scheper; Alfons J M van den Eertwegh; Winald R Gerritsen; Daniel J Powell; Carl H June; Tanja D de Gruijl Journal: J Transl Med Date: 2013-02-12 Impact factor: 5.531